News & Updates

People living with HIV (PLWH) are less likely to receive preventive cardiovascular (CV) care than non-HIV-infected patients, suggest the results of a study conducted in the same outpatient clinic.

A large global study of patients with severe COVID-19 admitted to the intensive care unit (ICU) has shown a 14 percent prevalence of haemorrhagic, coagulopathic, and thrombotic (HECTOR) complications in these patients, with mortality risk increased in those with haemorrhagic complications. 

People living with HIV (PLWH) are less likely to receive appropriate statin therapy for the prevention of atherosclerotic cardiovascular disease (ASCVD), a study has found.

Hospitalized patients with COVID-19 who are receiving remdesivir and other standard care show no improvements in clinical outcomes with the addition of ensovibep, according to the results of a study.

Incident tuberculosis (TB) appears to be a risk factor for virologic non-suppression (ie, viral load of >1,000 copies/mL) in HIV patients who have transitioned to dolutegravir (DTG)-based therapy with recycled NRTIs*, according to a retrospective subanalysis of the VISEND study.

Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.

Hope springs yet again in the field of HIV treatment, as another HIV patient (reportedly the fourth in the world) goes into remission 3 decades following diagnosis. The patient stopped antiretroviral therapy (ART) after receiving allogeneic hematopoietic stem cell transplantation (HCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukaemia (AML).

Immunizations with mRNA-based vaccines are strongly effective against symptomatic and severe COVID-19 disease associated with the virus’ Delta variant, according to a recent Singapore study.